Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1629

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7
Chunk 1629
---
 of shares of common stock outstanding from 21,219,937 shares to 1,768,337 shares (not including the effects of the
1:5 Reverse Stock Split discussed below). No fractional shares of common stock were issued in connection with the Reverse Stock Split
and all fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. The Company
issued an additional 18,710 shares of common stock on August 19, 2024 for rounding due to fractional shares (93,563 not including the
effects of the 1:5 Reverse Stock Split discussed below).

Following stockholder approval in November 2024,
on February 18, 2025, the Company filed an additional Amendment to the Certificate of Incorporation with the Secretary of State of Delaware
to effect the 1:5 Reverse Stock Split of the issued and outstanding shares of the Company’s common stock, which was effective as
of February 24, 2025. As of the effective time of the 1:5 Reverse Stock Split, every five (5) issued and outstanding shares of the Company’s
common stock were automatically combined and converted into one (1) issued and outstanding share of the Company’s common stock,
reducing the number of shares of common stock outstanding from 7,364,554 shares to 1,472,891 shares. No fractional shares of common stock
were issued in connection with the 1:5 Reverse Stock Split. All fractional shares were rounded up to the nearest whole share with respect
to outstanding shares of common stock. See Note 12 - Subsequent Events.

The Reverse Stock Splits did not change the authorized
number of shares of common stock or preferred stock, the par value of the common stock, or the number of issued and outstanding shares
of Series A Preferred Stock. All references to numbers of shares of the Company’s common stock and per share information in these
consolidated financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying
an amount equal to the reduction in par value of common stock to additional paid-in capital.

Common Stock

In January and March 2023, the Board of Directors,
with the consent of Tyrone Miller and Geoffrey S. Dow, respectively, approved resolutions to cancel an aggregate of 3,203 shares of common
stock issued to Tyrone Miller and 20,983 shares of common stock issued to the Geoffrey S. Dow Revocable Trust